GeneCentric launches with UNC licenses
DURHAM, N.C.—GeneCentric announced at the end of August two exclusive licenses to diagnostic platform technologies from the University of North Carolina at Chapel Hill (UNC-Chapel Hill). GeneCentric has in-licensed the Lung Subtype Platform from UNC-Chapel Hill, technology that can determine several subtypes of lung cancer based on genetic fingerprints from tumor samples. The second licensing agreement grants GeneCentric exclusive worldwide commercial rights to a 13-gene vascular endothelial growth factor signature that is associated with distant metastases as well as poor outcomes. Financial details were not disclosed.
"The next era of cancer clinical trials and, in fact, cancer care will be driven by a tumor's molecular signature," Shelley Earp, director of UNC Lineberger Comprehensive Cancer Center, said in a press release regarding the license agreements.